Author:
Blackhall Fiona,Jao Kevin,Greillier Laurent,Cho Byoung Chul,Penkov Konstantin,Reguart Noemi,Majem Margarita,Nackaerts Kristiaan,Syrigos Konstantinos,Hansen Karin,Schuette Wolfgang,Cetnar Jeremy,Cappuzzo Federico,Okamoto Isamu,Erman Mustafa,Langer Seppo W.,Kato Terufumi,Groen Harry,Sun Zhaowen,Luo Yan,Tanwani Poonam,Caffrey Laura,Komarnitsky Philip,Reinmuth Niels
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference25 articles.
1. Small-cell lung cancer: what we know, what we need to know and the path forward;Gazdar;Nat Rev Cancer,2017
2. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer;Horn;N Engl J Med,2018
3. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial;Paz-Ares;Lancet,2019
4. Novartis Pharmaceuticals Corporation. Hycamtin (Topotecan) prescribing information. https://www.novartis.us/sites/www.novartis.us/files/hycamtin_caps.pdf. Accessed March 11, 2021.
5. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
Cited by
144 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献